Does poor TTR control increase adverse clinical outcomes in patients with NVAF on warfarin?
Maintaining a Time in Therapeutic Range (TTR) ≥65% is crucial for minimizing adverse clinical outcomes in patients with non-valvular atrial fibrillation taking warfarin.
Poor TTR control is associated with adverse clinical outcomes in patients with NVAF who were on warfarin. Efforts to ensure good TTR (≥65%) after initiation of warfarin are mandatory to minimize the risk of adverse clinical outcomes.
Krittayaphong et al. (Tue,) studied this question.